Targeting Alpha-Amylase: Discovering Novel Inhibitors through E-Pharmacophore Modeling and in vitro studies

Indian Journal of Pharmaceutical Education and Research

  • Norah Saeed Al-Zahrani1Department of Clinical Biochemistry, College of Medicine, King Khalid University, Abha, SAUDI ARABIA.
  • Basiouny El-Gamal1Department of Clinical Biochemistry, College of Medicine, King Khalid University, Abha, SAUDI ARABIA., 2Healthcare and Pharma Department, Planaletix, Dubai, UNITED ARAB EMIRATES.
  • Mohamed Abd Ellatif1Department of Clinical Biochemistry, College of Medicine, King Khalid University, Abha, SAUDI ARABIA., 3Department of Medical Biochemistry, Faculty of Medicine, Mansoura University, Mansoura, EGYPT.
  • Mohamed Babiker Abd Elrouf1Department of Clinical Biochemistry, College of Medicine, King Khalid University, Abha, SAUDI ARABIA.
  • Alam Eldin Musa Mustafa Musa4Department of Child Health, King Khalid University, Abha, SAUDI ARABIA., 5Department of Pediatrics, University of Kordofan, Al-Ubayyid, SUDAN.
  • Niemat Mohammed Tahir Ali4Department of Child Health, King Khalid University, Abha, SAUDI ARABIA.
  • Marya Ahsan6Department of Pharmacology, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, SAUDI ARABIA.
  • Ayaz Khurram Mallick1Department of Clinical Biochemistry, College of Medicine, King Khalid University, Abha, SAUDI ARABIA.
  • Ayyub Ali Patel1Department of Clinical Biochemistry, College of Medicine, King Khalid University, Abha, SAUDI ARABIA.
  • Safaa Omer1Department of Clinical Biochemistry, College of Medicine, King Khalid University, Abha, SAUDI ARABIA.
  • Muniera Mohieldeen1Department of Clinical Biochemistry, College of Medicine, King Khalid University, Abha, SAUDI ARABIA.
  • Hagar Mohamed Mohamed7Department of Medical Laboratory Analysis, Faculty of Medical and Health Sciences, Liwa University, Abu Dhabi, UNITED ARAB EMIRATES., 8Department of Applied Medical Chemistry, Medical Research Institute, Alexandria University, Alexandria, EGYPT.
  • Marwa Saeed1Department of Clinical Biochemistry, College of Medicine, King Khalid University, Abha, SAUDI ARABIA.
  • Safa Mousa Al-Haider4Department of Child Health, King Khalid University, Abha, SAUDI ARABIA.
  • Mohammed Abdullah Alshehri4Department of Child Health, King Khalid University, Abha, SAUDI ARABIA.

Volume 60 Issue 1 Pages 383-392

DOI: 10.5530/ijper.20261204

Abstract

Background: Diabetes mellitus is a metabolic disorder affecting millions worldwide, with prevalence continuing to rise globally. A major therapeutic challenge is controlling postprandial blood glucose spikes that contribute to chronic hyperglycemia and associated vascular complications in diabetes. Pancreatic alpha-amylase is a key enzyme responsible for digesting dietary carbohydrates into absorbable sugars, making it an attractive target for managing postprandial hyperglycemia. While inhibitors like acarbose are available, side effects limit their use. Structure-guided drug design can reveal improved candidates. Materials and Methods: The X-ray structure of acarbose-bound alpha-amylase guided pharmacophore modeling to encode critical chemical features for inhibition. Database screening retrieved compounds matching this bioactive geometry. Top hits through pharmacophore modeling were evaluated through molecular docking versus co-crystallized references. Results: A validated 7-feature pharmacophore model captured essential hydrogen bonding and shape complementarity constraints within the enzyme active site. Screening retrieved distinct chemotypes scored well on pharmacophoric fit and strain energy. Molecular docking confirmed the top hit CID70684192 having strong predicted affinity (binding energy -7.1 kcal/mol) through conserved polar contacts and shape complementarity. In in vitro studies, CID: 70684192 showed no significant effect on the viability of AR4-2J pancreatic cells at various concentrations and exposure times. However, treatment of rat AR42J pancreatic cells with IC50 concentration CID: 70684192 (7 nM) significantly decreased alpha-amylase activity in treated cells compared to control. Conclusion: An integrated in silico and in vitro approach discovered novel alpha-amylase inhibitors with robust computational evidence of improved predicted activity over existing drugs. These represent promising candidates for experimental testing to reveal better tolerated therapies aiding diabetes management and postprandial glucose control. Structure-guided design enabled rapid identification of bioactive small molecules from chemical space.

Keywords

  • Acarbose
  • Alpha-Amylase
  • Database Screening
  • Diabetes mellitus
  • E-pharmacophore
  • Voglibose
IJOPP

Loading…